Stock Research for PBYI


Featured Broker: Ally Invest

Get the due diligence for another stock.


PBYI Stock Chart & Research Data

The PBYI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PBYI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


PBYI Due diligence Resources & Stock Charts

The PBYI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View PBYI Detailed Price Forecast - CNN Money CNN View PBYI Detailed Summary - Google Finance
Yahoo View PBYI Detailed Summary - Yahoo! Finance Zacks View PBYI Stock Research & Analysis -

Stock Analysis

TradeIdeas View PBYI Trends & Analysis - Trade-Ideas Barrons View PBYI Major Holders - Barrons
NASDAQ View PBYI Call Transcripts - NASDAQ Seeking View PBYI Breaking News & Analysis - Seeking Alpha
Spotlight View PBYI Annual Report - OTC Report View PBYI OTC Short Report -
TradeKing View PBYI Fundamentals - TradeKing Charts View PBYI SEC Filings - Bar Chart
WSJ View Historical Prices for PBYI - The WSJ Morningstar View Performance/Total Return for PBYI - Morningstar
MarketWatch View the Analyst Estimates for PBYI - MarketWatch CNBC View the Earnings History for PBYI - CNBC
StockMarketWatch View the PBYI Earnings - StockMarketWatch MacroAxis View PBYI Buy or Sell Recommendations - MacroAxis
Bullish View the PBYI Bullish Patterns - American Bulls Short Pains View PBYI Short Pain Metrics -

Social Media Mentions

StockTwits View PBYI Stock Mentions - StockTwits PennyStocks View PBYI Stock Mentions - PennyStockTweets
Twitter View PBYI Stock Mentions - Twitter Invest Hub View PBYI Investment Forum News - Investor Hub
Yahoo View PBYI Stock Mentions - Yahoo! Message Board Seeking Alpha View PBYI Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for PBYI - Insider Cow View Insider Transactions for PBYI - Insider Cow
CNBC View PBYI Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for PBYI - OTC Markets
Yahoo View Insider Transactions for PBYI - Yahoo! Finance NASDAQ View Institutional Holdings for PBYI - NASDAQ

Stock Charts

FinViz View PBYI Stock Insight & Charts - StockCharts View PBYI Investment Charts -
BarChart View PBYI Stock Overview & Charts - BarChart Trading View View PBYI User Generated Charts - Trading View

Latest Financial News for PBYI

Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why
Posted on Friday January 11, 2019

Puma Biotech's (PBYI) only marketed drug, Nerlynx, is suffering low sales due to higher patient discontinuations.

Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada
Posted on Friday January 11, 2019

Puma Biotechnology, Inc. , a biopharmaceutical company, announced that it has entered into an exclusive License Agreement with Knight Therapeutics Inc. that grants Knight the exclusive right to commercialize NERLYNX® in Canada.

Knight Therapeutics Runs with Exclusive Canadian License to Puma’s NERLYNX®
Posted on Friday January 11, 2019

Puma filed a New Drug Submission for NERLYNX® with Health Canada in July 2018 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy. Under the terms of the License Agreement, Knight will be responsible for all commercial activities and future regulatory submissions for NERLYNX® in Canada.

Athenex Completes Enrollment Target for Breast Cancer Study
Posted on Thursday January 10, 2019

Athenex (ATNX) has completed target enrollment in the Oraxol phase III study in metastatic breast cancer on schedule.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.